dc.contributor.author | De Vuyst, Hugo | |
dc.contributor.author | Ndirangu, Gathari | |
dc.contributor.author | Moodley, Manivasan | |
dc.contributor.author | Tenet, Vanessa | |
dc.contributor.author | Estambale, Benson B | |
dc.contributor.author | Meijer, Chris JLM | |
dc.contributor.author | Snijders, Peter JF | |
dc.contributor.author | Clifford, Gary | |
dc.contributor.author | Franceschi, Silvia | |
dc.date.accessioned | 2013-03-19T15:45:37Z | |
dc.date.available | 2013-03-19T15:45:37Z | |
dc.date.issued | 2012-04-19 | |
dc.identifier.citation | http://www.infectagentscancer.com/content/7/S1/O12 | |
dc.identifier.uri | http://dx.doi.org/10.1186/1750-9378-7-S1-O12 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/14688 | |
dc.description.abstract | Data on the prevalence of human papillomavirus (HPV) types in invasive cervical carcinoma (ICC) in women with HIV are scarce but are essential to elucidate the influence of immunity on the carcinogenicity of different HPV types, and the potential impact of prophylactic HPV vaccines in populations with high HIV prevalence | |
dc.title | Human papillomavirus prevalence in invasive cervical carcinoma by HIV Status | |
dc.type | Journal Article | |
dc.date.updated | 2013-03-19T15:45:37Z | |
dc.description.version | Peer Reviewed | |
dc.language.rfc3066 | en | |
dc.rights.holder | Hugo De Vuyst et al.; licensee BioMed Central Ltd. | |